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A review ofdirect current cardioversions for atrial
arrhythmia
S D Johnston, T G Trouton, C Wilson
SUMMARY
The risk ofarterial embolism is well recognised following Direct Current Cardioversion (DCC)
for atrial fibrillation although the use ofprophylactic anticoagulation remains controversial.
Aim: To determine the risk of arterial embolism post-cardioversion and which factors predict
successful cardioversion and maintenance of sinus rhythm.
MaterialsandMethods: Aretrospectivestudywascarriedoutofallcardioversionsperformedfor
atrial fibrillation and atrial flutter at the Waveney Hospital Ballymena, during 1989-1993. A
review of medical records and electrocardiograms was carried out to assess demographic
characteristics, co-existent diseases, anticoagulant status, echocardiographic features and
characteristicsofthearrhythmia. Embolic eventsinthesixweekspost-cardioversion werenoted.
Results: The study included 157 cardioversions in 109 patients. The predominant arrhythmia
was atrial fibrillation (n=108, 69%). Three of 109 patients (2.7%) experienced embolic
complications, none of whom had anticoagulation prior to the procedure. No risk factors for
cerebro-vascular disease or significant valvular heart disease were present. Return to sinus
rhythm was achieved in 143 (91%) procedures. Increasing coarseness of atrial fibrillation was
associated with a non-significant trend towards successful restoration ofsinus rhythm (p=O.l 8).
Recurrence of the original arrhythmia was predicted by an increase in coarseness of atrial
fibrillation (p<O.O5).
Conclusions: Thesefindingsindicatethatemboliccomplicationscanoccurinpatientsundergoing
DCC with normal echocardiographic dimensions, and that prophylactic anticoagulation should
be considered in all patients. Coarseness ofatrial fibrillation may be used as a guide to predict
thechanceofsuccessfulcardioversionandofthelikelihoodofmaintainingsinusrhythmoncethis
has been achieved.
INTRODUCTION
Atrial fibrillation is the commonest sustained
arrhythmia. Chronicatrialfibrillationisassociated
with a doubling of mortality,' largely due to an
increase inthe incidenceofstroke.2Thepotential
benefits ofareturntosinusrhythmareareduction
in the risk of systemic embolisation and an
improvement in haemodynamics secondary to
the return of atrial mechanical function.3
Return to sinus rhythm may occur spontaneously
or may be achieved by chemical or electrical
cardioversion. Direct Current Cardioversion
(DCC) in atrial fibrillation is a successful, safe
procedureandshouldbeconsideredforallpatients
regardless of aetiology. DCC is known to be
highly effective for the immediate conversion of
atrial fibrillation to sinus rhythm.4 The risk of
embolismfollowing DCC foratrial fibrillation is
wellrecognisedbuttheuseofroutineprophylactic
anticoagulationremains somewhatcontroversial.
Certain factors, such as duration of atrial
fibrillation, left atrial size as assessed by M-
mode echocardiography and aetiological
associations may be predictive of a successful
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restoration of sinus rhythm, although these have
not been confirmed by Dittrich.s
We reviewed the results of 202 cardioversions
for atrial fibrillation and atrial flutter over a five
year period to assess further the need for
prophylactic anticoagulation. Inaddition, wehave
attemptedtodeterminefactorspredictingtherisk
ofthrombo-embolismpost-cardioversion andalso
those parameters predicting successful cardio-
version and maintenance of sinus rhythm once
this had been achieved.
MATERIALS AND METHODS
Between 1st January 1989 and 31st December
1993, 202 elective DCC procedures were
undertaken in 116 adult patients (82 male) with
atrial fibrillation or atrial flutter as the primary
arrhythmia. Cardioversions in which atrial
fibrillation or atrial flutter were present for less
than 48 hours and cardioversions in which
anticoagulant status was indeterminate were
excluded from subsequent analysis.
All cardioversions were carried out in the
Coronary Care Unit under intravenous sedation
with midazolam (usual dose 5-10 mgs). A series
ofsynchroniseddirectcurrentshocksofincreasing
energy was delivered startingwith50Joules, and
increasing incrementally until sinus rhythm was
achieved or 360 Joules was reached. Pre- and
post-cardioversion 12-lead electrocardiograms
were available to verify heart rhythm.
The medical records were reviewed for
demographic characteristics and coexistent
diseases (ischaemic heart disease, valvular heart
disease, hypertension, diabetes mellitus or
cerebro-vascular disease). Electrocardiographs
were examined to confirm heart rhythm prior to
DCC and to determine the duration of the
arrhythmia. Inpatients with atrial fibrillation the
"coarseness" of atrial electrical activity was
assessed subjectively and determined to be
"coarse", "intermediate" or"fine", depending on
thebaselineatrialelectricalactivityandmean"f'
wavecyclelength. Inaddition, leftatrial size, left
ventricular end-diastolic diameter and the
presence or absence of valvular heart disease
were noted in those patients in whom
echocardiography had been performed.
Anticoagulant status was recorded and an
International Normalised Ratio greater than 1.5
was considered therapeutic. Suspected embolic
eventsinthesubsequent sixweeks wererecorded.
STATISTICS
Values, where applicable, are given as mean
(SD). Group comparisons of categoric variables
were madeusing the Chi-square test. Continuous
variables were compared by using the Mann
WhitneyU-test. Avalueofp<0.05wasconsidered
significant.
RESULTS
Two hundred and two procedures in 116 patients
were identified during the study period. Forty-
fivecardioversions wereexcludedfromthe study
on account ofcardioversion performed within48
hours of the onset of the arrhythmia (n=38) or
indeterminate anticoagulant status (n=7). The
studygroupthereforeconsistedof157procedures
in 109 patients. In 22 (14%) cardioversions
prophylactic anticoagulation with oral warfarin
had been prescribed prior to the procedure.
Ofthe 109patients, 77 (71%) weremale andtheir
ages ranged from 17 to 86 years (mean 65.0
(11.1) years). Seventy-five patients required
cardioversion on a single occasion and the
remaining 34 patients accounted for the other 82
cardioversions included in the study. The
predominant rhythm disturbance requiring
cardioversion was atrial fibrillation (atrial
fibrillation in 108, atrial flutter in 49
cardioversions). Concomitant ischaemic heart
disease was present in 31 patients (28%), mitral
valve disease in 33 patients (30%), hypertension
in24patients(22%),diabetesmellitusin4patients
(4%) and a history of prior cerebro-vascular
accident in 3 patients (3%). Mitral valve disease
was significantly more prevalent in the
anticoagulatedgroup(p<0.05)whereasischaemic
heart disease was significantly more prevalent in
thegroupnotreceivinganticoagulation(p<0.05).
There was no significant difference in
anticoagulant status for the sub-groups with
hypertension(p=0.75),diabetesmellitus(p=0.33)
or previous cerebro-vascular disease (p=0.33)
(Table 1).
The duration of the arrhythmia ranged from 48
hours to two years. The duration was less than
eightdaysin80cardioversions (51%),eightto28
daysin40(25%), 29days to one yearin 36(23%)
and greater than one year in one cardioversion.
Twopatientshadprosthetic aortic valves andone
patient had both mitral and aortic prostheses.
Echocardiographic data was available in 52
patients (48%) in the study group. The mean left
atrial size was 49.9 (6.2) mm (range 36-61 mm).
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When the arrhythmia had been present for less
than 30 days the mean left atrial size was 49.8
(5.9)mmcomparedto50.3 (7.3)mmwhenpresent
for more than 30 days (p=0.89). The mean left
ventricularenddiastolic diameterwas56.2(10.1)
mm when the arrhythmia was present for less
than 30 days, compared to 56.6 (7.5) mm when
present for more than 30 days (p=0.98).
TABLE I
A comparison ofriskfactors presentfor cerebro-vascular disease between the groups ofpatients
undergoing cardioversion with and withoutprophylactic anticoagulation
Patients undergoing DCC Patients undergoing DCC
with prophylactic withoutprophylactic
anticiagulation anticoagulation
(n=18) (n=91)
Ischaemic heart disease 1 30 p<O.05
Mitral valve disease 10 23 p<O.05
Hypertension 3 21 p=0.75
Diabetes mellitus 1 3 p=0.33
Previous cerebro-vascular disease 0 3 p=0.33
No risk factors 3 11
EMBOLIC PHENOMENA
Cerebral embolic events occurred within six
weeks of DCC following two of 89 procedures
performed for atrial fibrillation and one of 46
proceduresperformedforatrialflutter,undertaken
without anticoagulant prophylaxis (Figure 1).
The patients were aged 55, 56, and 63 years
(mean 58 years). The arrhythmias were present
for 7, 10 and 50 days (mean 22 days). These
patientshadnoco-existentriskfactorsforcerebro-
vascular events. Echocardiographic data were
available intwoofthesepatients inwhomtheleft
atrial size, leftventricularend-diastolic diameter
andleftventricularfunctionwerenormal.Neither
had significant valvular heart disease; one had
mildmitralregurgitation andtheotherhadmitral
valve prolapse. One patient had a transient right
hemiparesis and right homonymous hemianopia
andwasprescribedaspirin.Theothertwopatients
experienced a left hemiparesis and both were
prescribed warfarin following CT brain scan
confirming an ischaemic infarction. No fatalities
resulted from these embolic events.
SUCCESSFUL CARDIOVERSION
Immediate restoration of sinus rhythm was
achieved in 143 (91%) ofthe 157 cardioversions
performed. In patients who were successfully
cardioverted to sinus rhythm the mean left atrial
sizewas49.9 (5.9)mmwhereasinpatientswhose
cardioversions were not successful the mean left
atrial sizewas49.2(9.7)mm(p=0.73). Inpatients
who were successfully cardioverted, the mean
left ventricular end-diastolic diameter was 56.1
(9.8) mm whereas in patients whose cardio-
versions werenotsuccessfulitwas58.2(4.0)mm
(p=0.73). Increasing coarseness of atrial
fibrillation was associated with a successful
restoration of sinus rhythm. All 19 patients with
coarse atrial fibrillation were successfully
cardioverted compared to 36 of 41 (88%) with
intermediateatrialfibrillation and30of36(83%)
of those with fine atrial fibrillation (p=O.18).
Age, duration of the arrhythmia, left ventricular
end-diastolic diameter and aetiology were not
predictive of successful restoration of sinus
rhythm.
Energyrequirementsinsuccessfulcardioversions
for atrial flutter were significantly lower than
those required for atrial fibrillation. Sixty-six
(69%) of 96 successful cardioversions for atrial
fibrillation required < 200 Joules whereas 42
(89%) of 47 successful cardioversions for atrial
flutter required < 200 Joules (p<O.OO1). Energy
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Figure 1
Summary of 157 cardioversions reviewed with relation to the
number of embolic events which occurred.
|A. Fibrillation || A. Flutter l
l n=108 ll n=49l
Anticoagulation No Anticoagulation Anticoagulation No Anticoagulation
n=19 n=89 n=3 n=46
Embolic 0 2 0 1
Events
requirements forthosepatients with coarse atrial
fibrillation were significantly lower compared
with thoserequired forintermediate orfine atrial
fibrillation (p=0.014). Table II shows the energy
requirements for 96 cardioversions for coarse,
intermediate and fine atrial fibrillation. One
cardioversion foratrial fibrillation had norecord
of the energy required for successful
cardioversion; eleven pre-DCC electrocardio-
grams were unavailable for analysis.
TABLE II
Energy Requirementsfor the subgroups of
Atrial Fibrillation undergoing Successful
Cardioversion (n=96)
Energy (J) Coarse Intermediate Fine
n(%) n(%) n(%)
50,100J 8(42) 1(2) 7(19)
150, 200J 9(47) 26(63) 15(42)
300,360J 2(11) 14(35) 14(39)
19(100%) 41(100%) 36(100%)
x2=8.47 p=0.014
RELAPSE RATES
Following successful restoration ofsinusrhythm
in 143cases,recurrenceoftheoriginalarrhythmia
occurred in 75 cases (52%). The mean time to
relapse was 217 days (range 1 day to45 months).
At one month 25 (17%) patients were found to
have relapsed, compared to 53 (37%) at six
months. Inpatients who subsequently revertedto
theiroriginalrhythmthe mean leftatrial size was
50.7 (5.9) mm compared to those who remained
in sinus rhythm in whom the mean left atrial size
was 48.8 (5.9) mm (p=0.43). In patients who
subsequently reverted to their original rhythm
the mean left ventricular end-diastolic diameter
was 55.8 (8.2) mm compared to those who
remained in sinus rhythm in whom the mean left
ventricular size was 56.4 (11.7) mm (p=O.9).
Seven of 19 cardioversions for coarse atrial
fibrillationresultedinarecurrenceoftheoriginal
rhythmcomparedto20of36forintermediate and
17 of 30 for fine atrial fibrillation (p<0.05).
Ischaemicheartdiseasewastheaetiologicalfactor
in 13 of 75 cardioversions which were followed
by arecurrence oftheoriginalrhythm, compared
to 23 of68 cardioversions in which sinus rhythm
was maintained (p<O.O1). Although a higher
number of patients with mitral valve disease,
hypertensionandunknownaetiologyexperienced
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a recurrence of the original rhythm, these
differences did not reach a significant level. The
age of the patient and the duration of the
arrhythmia were not predictive of relapse. The
effect of anti-arrhythmic agents on relapse rates
was not examined.
DISCUSSION
Synchronised electrical cardioversion for atrial
fibrillation and atrial flutter may be complicated
bysystemicembolisation. Thishasbeenestimated
to occur in up to 7% of patients.6 The atrial
arrhythmia most likely to be associated with
embolic events is atrial fibrillation,7' 8 although
oneofthreepatientsdevelopingcerebralthrombo-
embolism in our study had been cardioverted for
atrial flutter.
Although ithas been suggested thatpatients with
atrial fibrillation should receive anticoagulation
priortoundergoingdirectcurrentcardioversion,4 8
there has been a lack of consensus on such
treatment prior to the period included in this
study. Recently it has been recommended that
anticoagulation should be given for three weeks
before and four weeks after DCC for atrial
fibrillation of more than 48 hours duration.9
Datais sparse on the incidence ofembolism after
cardioversion for specific arrhythmias. Lown, in
1967, reported a 1.2% incidence rate of
embolisation after reviewing 456 cardioversion
attempts in which none of the patients were
anticoagulated.4 In 1969 Bjerkelund and Orning
reported that cardioversion without anti-
coagulation resulted in a 6.8% incidence rate of
embolism, compared with a significantly lower
rate of 1.1% with anticoagulation, following
successful cardioversion.10 Mancini and
Weinbergreviewedcardioversions overa 10year
period and found no embolic events in the group
prescribed anticoagulation, whereas 7% of the
group without anticoagulation had embolic
complications.11 Our 2.1% incidence rate of
embolic events aftersuccessful cardioversionfor
atrial fibrillation and atrial flutter is higher than
other reports.12-15
Atrial fibrillation of long duration is a well
documented risk factor for stroke.16 It has been
recommended7' 8 that patients with atrial
fibrillation of short duration (<1 week) do not
need anticoagulation before undergoing
cardioversion. In our three patients suffering
cerebral thromboembolism following DCC the
arrhythmia had been present for 7, 10 and 150
days respectively.
It remains unclear how long anticoagulation
therapy should be continued after cardioversion.
Mechanicalatrialactivitymaytakeseveralweeks
to resume as shown by Manning who assessed
patients by means of serial Doppler echo-
cardiography. They found that peak "A" wave
velocitydidnotreturntonormaluntilthreeweeks
after cardioversion in patients who maintained
sinus rhythm.17
Inourseriesofpatientswewereabletocardiovert
91% (143 of 157) of patients to sinus rhythm.
This is similar to results published by Dalzell.'8
Our findings show that smaller left atrial size is
not a useful factor in determining which patients
are more likely to be successfully cardioverted.
Zipes reports that the only important predictor is
the duration of atrial fibrillation.'9 The duration
ofthearrhythmiawasnotshowntobeasignificant
predictor in our study. We have identified
increasing coarseness of atrial fibrillation as a
usefulpredictorofsuccessfulrestorationofsinus
rhythm.
Without further treatment there is a high rate of
relapse following successful cardioversion. The
influence of anti-arrhythmic agents was not
considered in this review. Sinus rhythm was
maintained in 118 of 143 cases (82%) at one
month and 90 of 143 cases (63%) at 6 months
whichcomparesfavourablywiththoseofDittrich5
who has reported rates of69% and 58% at 1 and
6 months respectively. Useful and safe
prophylaxis of atrial fibrillation has been
demonstratedinselectedgroups ofpatientsusing
anti-arrhythmic drugs from different classes,
although a metanalysis of randomised control
trials in the use of quinidine has indicated an
increased total mortality.20'2'
Atrial fibrillation is acommon arrhythmia that is
associated with significant morbidity and
mortality. Directcurrentcardioversion shouldbe
considered in all patients regardless ofaetiology
since initial success rates are high. Our findings
indicate that embolic complications can occur in
patients undergoing direct current cardioversion
without prophylactic anticoagulation who have
normal echocardiographic findings and no risk
factors for cerebrovascular events. We therefore
recommend that prophylactic anticoagulation
should be considered in all patients with atrial
fibrillation or atrial flutter of>1 week's duration
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priortoattemptedcardioversion. Anticoagulation
should be given for4 weeks priorto and, atleast,
4 weeks following elective cardioversion.
Coarseness ofatrial fibrillation may be used as a
subjective guide to predicting the probability of
achieving and maintaining sinus rhythm. The
high relapse rates following successful
cardioversion remain problematic andtherole of
prophylactic anti-arrhythmic drugs and non-
pharmacological measures remains to be
established in these patients with recurrent atrial
arrhythmias.
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